[Inhibitors of proteolytic enzymes in the treatment of diabetes mellitus].
A new approach to overcome the degradation of insulin by proteolytic enzymes and its targeting to the blood through the digestive apparatus was developed. The approach is based on the immobilization of insulin into the polymeric hydrogel which is modified by ovomucoid--glycoprotein, inhibitor of proteolytic enzymes. Oral administration of this system to rabbits and rats, (in contrast to the hydrogels modified by proteolytic enzymes inhibitors without polysaccharide part), statistically significantly lowered blood glucose level.
Valuev
I L
IL
Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninsky prospekt 29, Moscow, 117912.
Sytov
G A
GA
Valuev
L I
LI
Valueva
T A
TA
Ul'ianova
M V
MV
Platé
N A
NA
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D004337:Drug Carriers; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D010059:Ovomucin / Q000008:administration & dosage*; D011817:Rabbits; D051381:Rats; D014361:Trypsin Inhibitors / Q000008:administration & dosage*
D004337:Drug Carriers; D007004:Hypoglycemic Agents; D007328:Insulin; D014361:Trypsin Inhibitors; D010059:Ovomucin